MECP2 and early-onset autosomal dominant Alzheimer disease: Furthermore, the neuronal nicotinic acetylcholine receptor agonists Nefiracetam and PHA 543613 developed for Alzheimer’s disease treatment can reverse synaptic defects observed in an induced human pluripotent stem cell model of MECP2 knockout cortical organoid (Trujillo et al., 2021).